Nisa Leung

Nisa Leung (Chinese:梁颕宇 or 梁颖宇) is a venture capitalist and managing partner at Qiming Venture Partners. She has been named on the Forbes Midas List for five consecutive years in 2019, 2020, 2021,2022 and 2023. and Best Women Venture Capitalists by Forbes China for three years. Nisa was also named one of the Most Powerful Women in Business in China by Fortune China in 2022 and 2023. Nisa is widely known as China's leading investor in healthcare.

Education
Nisa earned a Bachelor of Science degree from Cornell University and graduated from Stanford Graduate School of Business in 2001 with an MBA.

Career
Nisa started her career in healthcare investment after realizing there was a lack of advanced therapeutics in China when her family was seeking treatments for her distant uncle, who was diagnosed with liver cancer.

Prior to joining Qiming Venture Partners in 2006, she co-founded Biomedic Holdings, which had operations and investments in medical devices, pharmaceuticals, and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). She was also Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.

Leading Qiming's healthcare investments, Nisa has backed nearly 200 healthcare companies. She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics(SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan&Lee (SSE:603087), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR), Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.

Nisa is recognized as playing a key role in China's biotech boom and innovation.

She serves as Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited. She is also a visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA.